Literature DB >> 19059573

Short QT syndrome. Update on a recent entity.

Philippe Maury1, Fabrice Extramiana, Pascal Sbragia, Carla Giustetto, Rainer Schimpf, Alexandre Duparc, Christian Wolpert, Isabelle Denjoy, Marc Delay, Martin Borggrefe, Fiorenzo Gaita.   

Abstract

The short QT syndrome, a recently discovered ion channel disorder, combines shortened repolarization, a predisposition to atrial and ventricular fibrillatory arrhythmias, and a risk of sudden death. Few cases have been reported, but the prevalence may be underestimated. This syndrome might account for some cases of unexplained ventricular fibrillation in patients with otherwise healthy hearts. Patients have abnormally short QT intervals and refractory periods, and atrial/ventricular fibrillation can be triggered during investigations. Gain-of-function mutations have been detected in three genes encoding potassium channels. Treatment is based on defibrillator implantation, sometimes as a preventive measure. Quinidine may be beneficial in certain cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19059573     DOI: 10.1016/j.acvd.2008.08.009

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  15 in total

Review 1.  The short QT syndrome.

Authors:  Brian Cross; Munther Homoud; Mark Link; Caroline Foote; Ann C Garlitski; Jonathan Weinstock; N A Mark Estes
Journal:  J Interv Card Electrophysiol       Date:  2011-04-14       Impact factor: 1.900

Review 2.  Inherited primary arrhythmia disorders: cardiac channelopathies and sports activity.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; M Ben Miled; S Kachboura
Journal:  Herz       Date:  2018-05-09       Impact factor: 1.443

3.  Exercise, heart and health.

Authors:  Gi-Byoung Nam
Journal:  Korean Circ J       Date:  2011-03-31       Impact factor: 3.243

4.  The hERG K(+) channel S4 domain L532P mutation: characterization at 37°C.

Authors:  Yi H Zhang; Charlotte K Colenso; Richard B Sessions; Christopher E Dempsey; Jules C Hancox
Journal:  Biochim Biophys Acta       Date:  2011-07-14

5.  Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndrome.

Authors:  Ismail Adeniran; Mark J McPate; Harry J Witchel; Jules C Hancox; Henggui Zhang
Journal:  PLoS Comput Biol       Date:  2011-12-15       Impact factor: 4.475

6.  In silico investigation of a KCNQ1 mutation associated with short QT syndrome.

Authors:  Ismail Adeniran; Dominic G Whittaker; Aziza El Harchi; Jules C Hancox; Henggui Zhang
Journal:  Sci Rep       Date:  2017-08-16       Impact factor: 4.379

7.  In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.

Authors:  Cunjin Luo; Kuanquan Wang; Henggui Zhang
Journal:  PLoS One       Date:  2017-06-20       Impact factor: 3.240

8.  hERG1a/1b heteromeric currents exhibit amplified attenuation of inactivation in variant 1 short QT syndrome.

Authors:  M J McPate; H Zhang; J M Cordeiro; C E Dempsey; H J Witchel; J C Hancox
Journal:  Biochem Biophys Res Commun       Date:  2009-06-06       Impact factor: 3.575

9.  Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.

Authors:  Aziza El Harchi; Dario Melgari; Yi Hong Zhang; Henggui Zhang; Jules C Hancox
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

10.  Shortening of the Short Refractory Periods in Short QT Syndrome.

Authors:  Anne Rollin; Estelle Gandjbakhch; Carla Giustetto; Chiara Scrocco; Carole Fourcade; Benjamin Monteil; Pierre Mondoly; Christelle Cardin; Carole Maupain; Fiorenzo Gaita; Philippe Maury
Journal:  J Am Heart Assoc       Date:  2017-05-31       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.